Clinical Laserthermia Systems (CLS) Q4 2025 earnings summary

Executive summary

• Achieved 67% gross margin in 2025, surpassing the 60% target, and reduced operating expenses by 38% year-over-year, exceeding the 30% reduction goal.

• Prism product sales in neurosurgery grew 14% year-over-year, driven by increased procedures through a strategic partner.

• Total net sales declined 7% to SEK 17.5 million due to reduced activity outside neurosurgery and alignment discussions on scaling.

• Expanded FDA clearance for Prism system to include 1.5T and 3.0T MRI guidance, more than doubling the U.S. addressable market.

• Raised SEK 35 million in capital and remained debt-free.

Financial highlights

• Net sales for 2025 were SEK 17.5 million, down from SEK 18.8 million in 2024.

• Operating profit improved by SEK 25.4 million year-over-year, but remained negative at SEK -28.8 million.

• Loss for the year was SEK -41.6 million, an improvement from SEK -47.6 million in 2024.

• Earnings per share improved to SEK -1.6 from SEK -4.3 year-over-year.

• Equity ratio increased to 87% from 84% year-over-year.

Outlook and guidance

• Targets for 2026 maintained: positive cash flow in Q4 2026, gross margin above 60%, and double-digit revenue growth.

• Continued focus on commercial execution and scaling, with expansion of partnership model outside neurosurgery.

• Board and management are evaluating capital structure alternatives to ensure financial flexibility.